Safety of ACEi and ARB in COVID-19 management: A retrospective analysis

Sabina Kumar MS, DO1 | Mastaneh Nikravesh MD1 | Umeh Chukwuemeka MD1 | Michael Randazzo MD1 | Peter Flores MD1 | Prithi Choday MD1 | Ajith Raja BA1 | Mahendra Aseri MS1 | Shah Shivang MPH, MD2,3 | Sumanta Chaudhuri MD1 | Pranav Barve MPH, MD1

1Department of Internal Medicine, Hemet Global Medical Center, Hemet, California, USA
2Division of Cardiology, Loma Linda University School of Medicine, Loma Linda, California, USA
3Division of Cardiology, University of California Riverside School of Medicine, Riverside, California, USA

Correspondence
Pranav Barve, MPH, MD, Hemet Global Medical Center, 1117 East Devonshire Ave, Hemet, CA 92543, USA.
Email: barve.md@sevenstar.health

Abstract

Background & Aims: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a highly contagious virus that has infected 260 million individuals since December 2019. The severity of coronavirus disease 2019 (COVID-19) depends upon the complex interplay between viral factors and the host’s inflammatory response, which can trigger a cascade eventually leading to multiorgan failure. There is contradictory evidence that angiotensin-converting enzyme (ACEi) or angiotensin receptor blockers (ARBs) may affect mortality in patients with severe COVID-19, theoretically due to interaction with the bradykinin pathway. Therefore, we aim to explore the association between ACEi and ARB use and mortality in severe SARS-CoV2 infection. Severe acute respiratory syndrome with coronavirus (SARS-CoV2) is a highly contagious virus that has infected 260 million individuals since December 2019. The severity of COVID-19 depends upon the complex interplay between viral factors and the host’s inflammatory response, which can trigger a cascade eventually leading to multiorgan failure. There is contradictory evidence that angiotensin-converting enzyme (ACEi) or angiotensin receptor blockers (ARBs) may affect mortality in patients with severe COVID-19, theoretically due to interaction with the bradykinin pathway. Therefore, we aim to explore the association between ACEi and ARB use and mortality in severe SARS-CoV2 infection.

Materials & Methodology: This multicenter retrospective observational study enrolled 2935 COVID-19 patients admitted at six hospitals in Southern California, USA, between March 2020 and August 2021. Our primary outcome was the association of pre-hospital use of ACEi and ARB on in-hospital mortality in COVID-19 patients. First, relevant deidentified patient data were extracted using an SQL program from the electronic medical record. Then, a bivariate analysis of the relationship between ACEi and ARB use and different study variables using \( \chi^2 \) and t
test was done. Finally, we did a backward selection Cox multivariate regression analysis using mortality as a dependent variable.

Results: Of the 2935 patients in the study, hypertension was present in 40.6%, and congestive heart failure in 13.8%. ACEi and ARB were used by 17.5% and 11.3% of patients, respectively, with 28.8% of patients on either medication. After adjusting for confounding variables in the multivariate analysis, the use of ACEi (HR: 1.226, 95% CI: 0.989–1.520) or ARB (HR: 0.923, 95% CI: 0.701–1.216) was not independently associated with increased mortality.

Conclusion: Our results are consistent with the clinical guidelines and position statements per the International Society of Hypertension, that there is no indication to stop the use of ACEi/ARB in COVID-19 patients.

Keywords
ACEi, ARB, COVID-19, hypertension, mortality, safety

1 | INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a highly pathogenic and contagious virus which has infected 500 million individuals since December 2019. It is known to primarily affect the respiratory system, creating flu-like symptoms which can eventually lead to severe hypoxia and acute respiratory distress syndrome (ARDS). The severity of coronavirus disease 2019 (COVID-19) can range depending on the complex interplay between viral factors and the host's inflammatory response which can trigger a cascade eventually leading to multiorgan failure.

According to Yang et al., the patients with COVID-19 with comorbidity of hypertension (HTN) had a higher death rate (10.3%) and were more critically ill (18.3%) as compared with individuals without HTN. Since the onset of COVID-19, HTN has been found to be a major risk factor in patients. The incidence of HTN and COVID-19 were reported by the Chinese Center for Disease Control to be 12.8% worldwide, while other studies have reported as high as 30% and 31%. Angiotensin-converting enzyme (ACEi) and angiotensin receptor blockers (ARB) are the most widely prescribed antihypertensives in the market. There is contradictory evidence that ACEi or ARBs may either worsen or improve COVID-19 symptoms. The proposed mechanism is discussed below.

ACE2 is a glycoprotein that is expressed in the kidney, intestine, endothelium, lungs, and heart. It is hypothesized to bind with the spiked glycoprotein in SARS-CoV2. Once the binding occurs, SARS-CoV2 can cause downregulation of ACE2 resulting in increased concentrations of angiotensin II causing severe lung injury. ACEi reduce angiotensin II levels which increases the proportion of ACE-2; ARBs increase angiotensin II levels by blocking its coupling with AT2 receptor leading to upregulation of ACE-2 in the membrane. Some studies say that the availability of ACE-2 is directly correlated with the severe inflammatory response in COVID-19 while others claim that the free form of ACE-2 may inactivate SARS-CoV2 and subsequently prevent the virus from entering the lungs.

We aim to explore the association between pre-hospital use of ACEi and ARBs and mortality in patients with COVID-19. Most of the randomized trials to date have underpowered clinical endpoints and therefore cannot comment on the safety of ACEi and ARBs on adults with COVID-19. Our study is the largest multicenter retrospective study to date with a sample size of greater than 2900 patients commenting on prior ACEi or ARB usage on mortality in COVID-19.

2 | METHODS
This multicenter retrospective observational study was conducted at six hospitals in Southern California, USA. The study enrolled 2935 COVID-19 patients admitted to six hospitals between March 2020 and August 2021. All patients were confirmed to have COVID-19 infection through a positive PCR nasopharyngeal swab. Relevant de-identified patient data were extracted using a structured query language (SQL) program from the electronic medical record, which included: age, gender, race, comorbidities, laboratory results on admission, date of hospital admission, date of discharge, medications they received while on admission, heart rate, and disposition at discharge. Our primary outcome was in-hospital mortality of COVID-19 patients who were taking ACEi or ARBs before hospitalization versus those who were not.

A univariate analysis of the independent variables was performed which included: patients' age, gender, ethnicity, marital status, comorbidities, the medication patients received while in the hospital, and laboratory results using means and percentages. Furthermore, a bivariate analysis was performed of the relationship between ACEi and ARB use and different study variables using χ² and t test, with a p value of 0.05 considered significant. Finally, a backward selection Cox multivariate regression analysis was performed using mortality as a
dependent variable. Biologically plausible or statistically significant variables from the bivariate analysis, such as age, sex, body mass index (BMI), comorbidities, use of ACEi or ARB, intensive care unit (ICU) admission, and mechanical ventilation, were used as independent variables in the multivariate model. The effect was expressed in terms of hazards ratio, and hypothesis testing was done using a two-sided test, and an α value of 0.05 indicated statistical significance. Statistical analysis was completed using IBM SPSS version 27. The study was approved by the WIRB-Copernicus Group (WCG) institutional review board (IRB).

3 | RESULTS

3.1 | Descriptive statistics

Tables 1 and 2 show the breakdown of continuous and categorical variables of the study population, including length of stay, age, and BMI. The age ranged between 19 and 110 years. The group’s mean age ± standard deviation (SD) was 61.46 ± 18.35. There were 1276 female patients (44%) and 1656 male patients (56%). The mean BMI of the study group was 30.05, which was characterized as obese. The mean value ± SD of the inflammatory markers, c-reactive protein (CRP), lactate dehydrogenase (LDH), Ferritin, Troponin, and creatinine phosphokinase (CPK) were 13.79 ± 9.55, 447.40 ± 464.91, 916.13 ± 1861.28, 0.48 ± 2.40, and 715.52 ± 4262.20, respectively. HTN was present in 40.6% of the study group. ACEi or ARB use was present in 17.5% and 11.3%, respectively, with a total of 28.8% of patients on either medication. 43.8% of the study population received treatment with Remdesivir.

| TABLE 1 | Descriptive statistics of continuous variables |
| --- | --- |
| **Descriptive statistics** | **N** | **Minimum** | **Maximum** | **Median** | **Interquartile range** |
| Length of stay (days) | 2935 | 1 | 117 | 7.0 | 9.0 |
| Age (years) | 2935 | 19 | 110 | 63.0 | 26.0 |
| Body mass index (kg/m²) | 2814 | 13.97 | 83.12 | 28.34 | 8.78 |
| C-reactive protein (mg/dl) | 2375 | 0.04 | 54.38 | 12.95 | 12.77 |
| Lactate dehydrogenase (IU/L) | 1967 | 55 | 8180 | 363.0 | 261.0 |
| Ferritin (ng/ml) | 1836 | 5.1 | 47560.8 | 552.1 | 791.57 |
| Troponin (ng/ml) | 1788 | 0.01 | 32.78 | 0.04 | 0.06 |
| Creatinine phosphokinase (U/L) | 1184 | 0.04 | 88961.0 | 106.0 | 235.75 |
| Platelet (10³/µl) | 2877 | 21 | 1176 | 310 | 186.0 |
| White blood cell count (10³/µl) | 2873 | 1.8 | 80.7 | 12.5 | 9.1 |
| Potassium (meq/L) | 2266 | 2.70 | 10.50 | 4.5 | 1.0 |
| Thyroid-stimulating hormone (IU/ml) | 778 | 0.01 | 94.09 | 1.0 | 1.44 |
| Minimum heart rate | 2643 | 20 | 149 | 57.0 | 14 |

3.2 | Bivariate analysis

In the t test bivariate analysis of continuous variables, age, platelet count, and potassium were significantly associated with ACEi/ARB use. The mean age for patients on ACEi/ARB was 68.3 years compared to 58.7 for those not on ACEi/ARB (p < .001). The mean platelet count was 319,000/ml in those on ACEi/ARB compared to 334,000/ml in those not on ACEi/ARB (p = .01). Additionally, the mean potassium level was 4.8 meq/L in those on ACEi/ARB compared to 4.6 meq/L in those not on ACEi/ARB (p < .001) (Table 3). The length of stay (LOS) was similar for both patients with or without ACEi/ARB use, and the average LOS was 11 days (Table 3).

In the χ² bivariate analysis of categorical variables, race (p = .04), diabetes (p < .001), acute kidney injury (AKI) (p < .001), chronic kidney disease (CKD) (p = .002), congestive heart failure (CHF) (p < .001), chronic obstructive pulmonary disease (COPD) (p < .001), and coronary artery disease (CAD) (p < .001) were significantly associated with pre-hospital ACEi/ARB use. Patients with diabetes (17.7% vs. 15.7%), HTN (63.5% vs. 31.4%), AKI (12.2% vs. 7.4%), CKD (23.4% vs. 18.3%), CHF (22% vs. 10.5%), COPD (7.1% vs. 4.1%), and CAD (88.9% vs. 57.7%) were more likely to be on ACEi or ARBs compared to those who were not. In addition, mortality was higher for patients on ACEi or ARB compared to those who were not (27% vs. 20.3%) (p < .001) (Table 4). Furthermore, in the subgroup analysis mortality was higher in patients on ACEi (28.7%) compared to those on ARB (24.3%) (Table 5).

In the Kaplan–Meier bivariate survival analysis model (Figure S1), patients on ACEi had increased mortality compared with those not taking ACEi (p = .003). However, there was no statistically significant difference in mortality between patients who received ARBs and those who did not (p = .171) (Figure S2).
3.3 | Multivariate analysis

Backward selection Cox-regression multivariate analysis was performed to determine whether ACEi/ARB use was independently associated with mortality (Table S6). In the multivariate analysis, the use of ACEi was not independently associated with mortality (HR: 1.226, 95% CI: 0.989–1.520). Similarly, the use of ARB was also not associated with mortality (HR: 0.923, 95% CI: 0.70–1.216).

3.4 | Subgroup analysis

Multivariate subgroup analysis was performed to investigate other patient demographic factors or comorbidities which may be independently related to mortality in patients who received ACEi/ARB. Similar to our primary analysis, our multivariate subgroup analysis showed that ACEi/ARB use was not associated with mortality in the subset of patients with CHF and those without CHF. Similarly, ACEi/ARB use was not associated with mortality in patients with CKD versus those without CKD, and those aged 65 and above versus those below 65.

4 | DISCUSSION

During the COVID-19 pandemic, most of the patients who required hospitalization already had pre-existing comorbidities such as CAD and HTN. Per Suleyman et al.’s recent case-control study, 94% of
their inpatient study population diagnosed with COVID-19 had at least one comorbidity, including HTN (63.7%), CKD (39.3%), and diabetes (38.4%). This is also supported by Martins-Filho et al.'s study where diabetes, HTN, CKD, CAD, CHF, and COPD were noted as possible risk factors for mortality from COVID-19.

The two studies cited above were similar to our study population in terms of respective proportion of comorbidities. According to Martin-Filho et al.'s meta-analysis of COVID risk factors for mortality, the male sex accounts for an increased risk of in-hospital death due to COVID-19. In our study, males accounted for 61.3% of in-hospital COVID-19 deaths with a significant p value of 0.005 in the bivariate analysis (Table S7).

According to Peterson et al.'s retrospective cohort study on CAD association with COVID-19 mortality, CAD alone was not associated with mortality. However, it was noted that CAD patients affected by COVID-19 also had higher rates of other comorbidities.

TABLE 3  Bivariate analysis of the relationship between continuous variables and use of ACE/ARB

| Variable                                | ACEi or ARB | N    | Mean   | Std. deviation | pvalue |
|-----------------------------------------|-------------|------|--------|----------------|--------|
| Length of hospital stay (days)          | Yes         | 846  | 10.75  | 10.94          | .69    |
|                                         | No          | 2089 | 10.57  | 11.38          |        |
| Age (years)                             | Yes         | 846  | 68.27  | 14.55          | <.001  |
|                                         | No          | 2089 | 58.71  | 19.01          |        |
| Body mass index (kg/m²)                 | Yes         | 812  | 30.54  | 8.31           | .045   |
|                                         | No          | 2002 | 29.85  | 8.38           |        |
| C-reactive protein (mg/dl)              | Yes         | 708  | 13.57  | 9.33           | .44    |
|                                         | No          | 1667 | 13.89  | 9.64           |        |
| Lactate dehydrogenase (IU/L)            | Yes         | 590  | 454.03 | 486.55         | .68    |
|                                         | No          | 1377 | 444.56 | 455.48         |        |
| Ferritin (ng/ml)                        | Yes         | 551  | 856.82 | 1184.83        | .27    |
|                                         | No          | 1285 | 941.57 | 2085.07        |        |
| Creatinine phosphokinase (U/L)          | Yes         | 394  | 486.64 | 2037.02        | .19    |
|                                         | No          | 790  | 829.67 | 5013.18        |        |
| Platelet (10³/ml)                       | Yes         | 824  | 319.38 | 134.67         | .01    |
|                                         | No          | 2053 | 334.04 | 145.73         |        |
| White blood cell count (10³/ml)         | Yes         | 824  | 14.60  | 8.73           | .94    |
|                                         | No          | 2049 | 14.57  | 8.42           |        |
| Potassium (meq/L)                       | Yes         | 690  | 4.80   | 0.91           | <.001  |
|                                         | No          | 1576 | 4.60   | 0.81           |        |
| Thyroid-stimulating hormone (IU/ml)     | Yes         | 241  | 2.18   | 3.49           | .80    |
|                                         | No          | 537  | 2.27   | 6.01           |        |
| Minimum heart rate                      | Yes         | 747  | 56.21  | 13.64          | .10    |
|                                         | No          | 1896 | 57.17  | 13.73          |        |

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.

After CAD, HTN was the second most prominent comorbidity in our study. The prevalence of HTN increases with age. The prevalence was 22.4% among adults aged 18–39 and increased to 54.5% among those aged 40–59, and 74.5% among those aged 60 years and over. In fact, high blood pressure was a primary or contributing cause of death for 516,955 people in the United States in 2019.

Many of the patients with comorbidities were already on antihypertensive medications such as ACEI/ARBs before hospitalization. As it relates to COVID-19, patients with HTN were found to be more critically ill than those without HTN. The prevalence of ACEI/ARB use in treating the patients with the above comorbidities suggests that the interactions of ACEI/ARB use in SARS-CoV2 outcomes are worth studying.

Considered a minimal risk but vital to treatment; ACEI/ARBs required further study, but in our review of the current literature, most of the randomized trials created have been underpowered in the sample size of adults with COVID-19. Therefore, we developed...
the largest multicenter retrospective study to date with a sample size of more than 2900 patients. We studied the outcomes in COVID-19 patients who received pre-hospital ACEi or ARBs versus those who did not, in order to show an association with in-hospital mortality between these two groups.

We found that ACEi/ARB use was not independently associated with mortality. Our results remained consistent in our subgroup analyses stratified by age and comorbidities including HTN, CAD, CHF, and CKD.

Our findings are overall similar to prior studies, which did not find any association between the use of ACEi/ARB and mortality. For example, we looked at the results of Huang et al., Mancia et al., and Reynolds et al. A report on 50 hospitalized patients in China found no difference in clinical characteristics between ACEi and ARBs, suggesting little effect on clinically significant severe symptoms of COVID-19. In a large, population-based study of 6272 COVID-19 patients from Italy, they found that ACEi and ARB had no significant association with the risk of COVID-19 disease. Similarly, another study in New York reported no association between ACEi and ARBs and either an increased likelihood of a positive or of severe illness. A new meta-analysis led by the International Society of Hypertension presented at the recent American Heart Association Scientific Sessions 2021 found that randomization of COVID-19 patients to renin-angiotensin system (RAS) inhibitors versus controls had no effect on short-term all-cause mortality (7.2% vs. 7.5%, relative risk 0.95; 95% CI: 0.69–1.30). This is the largest pooled analysis to date, and included 14 randomized controlled trials and 838 patients, and the first to directly compare ACEi versus ARBs. Furthermore, the International Society of Hypertension explained the importance of continuing to take the

| Variable                  | Use of ARB/ACEi | p value |
|---------------------------|-----------------|---------|
|                          | No              | Yes     |
| Gender                    | Male            | 1181 (56.5%) | 475 (56.1%) | .84 |
|                           | Female          | 908 (53.5%) | 371 (43.9%) |
| Race                      | White           | 1164 (55.7%) | 512 (60.5%) | .04 |
|                           | Asian           | 113 (5.4%) | 52 (6.1%) |
|                           | Black           | 74 (3.5%) | 34 (4.0%) |
|                           | Others          | 737 (35.3%) | 248 (29.3%) |
| Expired                   | Yes             | 425 (20.3%) | 228 (27.0%) | <.001 |
|                           | No              | 1664 (79.7%) | 618 (73.0%) |
| Ventilator use            | Yes             | 377 (18.0%) | 159 (18.8%) | .63 |
|                           | No              | 1712 (82.0%) | 687 (81.2%) |
| Intensive care unit admission | Yes         | 369 (17.7%) | 173 (20.4%) | .08 |
|                           | No              | 1719 (82.3%) | 673 (79.6%) |
| Diabetes mellitus         | Yes             | 328 (15.7%) | 234 (27.7%) | <.001 |
|                           | No              | 1761 (84.3%) | 612 (72.3%) |
| Hypertension              | Yes             | 655 (31.4%) | 537 (63.5%) | <.001 |
|                           | No              | 1434 (68.6%) | 309 (36.5%) |
| Chronic kidney disease    | Yes             | 382 (18.3%) | 197 (23.4%) | .002 |
|                           | No              | 1702 (81.7%) | 646 (76.6%) |
| Acute kidney injury       | Yes             | 154 (7.4%) | 103 (12.2%) | <.001 |
|                           | No              | 1935 (92.6%) | 743 (87.8%) |
| Congestive heart failure  | Yes             | 219 (10.5%) | 186 (22.0%) | <.001 |
|                           | No              | 1870 (89.5%) | 660 (78.0%) |
| Chronic obstructive pulmonary disease | Yes         | 86 (4.1%) | 60 (7.1%) | <.001 |
|                           | No              | 2003 (95.9%) | 786 (92.9%) |
| Coronary artery disease   | Yes             | 1205 (57.7%) | 752 (88.9%) | <.001 |
|                           | No              | 884 (42.3%) | 94 (11.1%) |

**TABLE 4** Bivariate analysis of the relationship between categorical variables and use of ARB/ACEi

| Variable                  | Use of ARB/ACEi | p value |
|---------------------------|-----------------|---------|
|                          | No              | Yes     |
| Cardiac arrest            | Yes             | 68 (14.7%) | 46 (18.6%) | .17 |
|                           | No              | 394 (85.3%) | 201 (81.4%) |

**TABLE 5** Mortality in the ACEi and ARB groups

| Variable                  | ACEi | ARB | None | p value |
|---------------------------|------|-----|------|---------|
| Expired                   | Yes  | 147 (28.7%) | 81 (24.3%) | <.001 |
|                           | No   | 366 (71.3%) | 252 (75.7%) | 1664 (72.9%) | <.001 |

**TABLE 4** (Continued)

| Variable                  | Use of ARB/ACEi | p value |
|---------------------------|-----------------|---------|
|                           | No              | Yes     |

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
medications as prescribed, due to the cardiovascular benefits and minimal risk.\textsuperscript{15}

However, the study with US Veterans by Li et al.\textsuperscript{16} found that the use of ACEi, but not of ARB, was associated with significantly increased odds of using mechanical ventilators; OR = 1.265, (1.010, 1.584) and OR = 1.210, (1.053, 1.39) among all COVID-19 patients. This is interesting because our Kaplan–Meier bivariate survival analysis - which did not adjust for confounding variables - demonstrated increased mortality in patients on ACEi, which was not demonstrated for patients on ARBs. Thus switching from high dose ACEi to ARB or other antihypertensives may help avoid ACEi-triggered harmful enhancement of severe bronchoalveolar BK-related hyperinflammation.\textsuperscript{17} One possible explanation is that the increased mortality seen with ACEi use was confounded by age, pre-existing HTN, and CHF, which are associated with both ACEi/ARB use and severe COVID-19.

Interestingly, some studies have demonstrated a decrease in mortality among patients on ARBs alone. While the clinical evidence that ARBs may limit pulmonary damage is scarce, Mortensen et al. studied 11,498 patients with pneumonitis, and showed mortality at 30 days was 13% in the total population, 30% with ACEi, and 4% with ARBs. ARB treatment during hospital stay was associated with lower mortality.\textsuperscript{18} Additional clinical studies are underway to investigate this trend further.

Our study was limited by the retrospective cohort design. All patients with documented COVID-19 infection from six Southern California hospitals were initially included in our study. The data collection was dependent on the results manually entered into the EMR, which may have caused discrepancies among the clinical variables. The limitations of using an administrative database include clerical error, limited precision of codes to describe the condition, or omission of comorbidity codes by billing or coding staff perceived irrelevant.\textsuperscript{19}

Furthermore, we cannot completely elucidate all the factors that impact the pathway from exposure to outcome between ACEi/ARB use and death. Our conclusion may have been drawn upon fallacy which overadjusts for factors that are not a part of the relationship between exposure and outcome.\textsuperscript{20}

While it is possible that there is increased mortality with ACEi use alone, that conclusion requires further research. Larger sample size and more studies are needed to achieve statistical significance to comment on the effects of ACEi alone. The lack of significance in the multivariate analysis could be due to an over-adjustment bias of confounders.\textsuperscript{20} In terms of hospital mortality, it is possible that we were unable to accurately reflect risk since the length of hospitalization may be a variable dependent on ACEi or ARB as well as comorbid conditions which could lead to ACEi or ARB prescriptions. The absence of long-term mortality is also a limitation.

The authors looked individually into pharmacy records to see if the patient was taking either ACEi or ARB before admission; however, the dose and duration were not included in the analysis. In addition, the discontinuation, addition, or change in these drugs were not taken into consideration. Additionally, ACEi/ARB use could be related to the clinical severity of the COVID-19 infection; therefore, a future analysis could exclusively study ICU patients.

More importantly, the mechanisms of bradykinin in COVID-19 are not fully understood, especially the pathophysiology of bradykinin. Studying the course of bradykinin and specifically its interaction with organs from exposure to ACEi/ARBs would help illustrate its true effect. Without this information, the true mortality risk cannot be demonstrated.

There are currently two approved drugs that target the kinin system: icatibant (bradykinin 2 receptor) and monoclonal antibody lanadelumab. Van de Veerendonk et al.\textsuperscript{21} investigated whether treatment with bradykinin 2 receptor antagonist icatibant could be used as a treatment strategy. Loss of ACE2 could lead to plasma leakage and activation of the plasma kallikrein-kinin system, which raises bradykinin levels.\textsuperscript{21} The case−control study found evidence of an association between icatibant use and improved oxygenation, suggesting a benefit if given the medication in the early stages of disease when patients are hypoxic and admitted to the hospital.\textsuperscript{21} Van de Veerendonk as well as a clinical trial in Cleveland are also investigating the use of lanadelumab in COVID-19 patients with pneumonia. Van de Veerendonk is currently using mass spectrometry to measure kallikreins in the plasma of COVID-19 patients. There are some limitations, as plasma kallikreins have a very short half-life of around two hours.

Future studies should focus on the effects of ACEi/ARBs with concomitant use of icatibant and Lanadelumab. It would be ideal to separate those taking ACEi from those taking ARBs to accurately determine the effect of each drug independently. Previous use of ACEi/ARBs could potentially downregulate ACE2, therefore, minimizing the effects of icatibant and Lanadelumab. However, without a larger sample size to cross-reference pre-existing use of ACEi/ARBs, it is difficult to truly quantify the benefits of these drugs.

4.1 | Conclusion

Our results are consistent with the clinical guidelines and position statements; that there is no indication to stop ACEi/ARB in COVID-19 patients. This is consistent with the International Society of Hypertension's 14 RCT meta-analysis by Gnanethiran et al. which showed no difference in all-cause mortality between subjects receiving ACEi/ARB and those receiving the placebo.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Sabina Kumar  https://orcid.org/0000-0003-3851-9142
Mastaneh Nikravesh  https://orcid.org/0000-0003-2990-7960
REFERENCES

1. Behl T, Kaur I, Bungau S, et al. The dual impact of ACE2 in covid-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci. 2020;257:118075. doi:10.1016/j.lfs.2020.118075

2. Yang G, Tan Z, Zhou L, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension. 2020;76(1):51-58. doi:10.1161/HYPERTENSIONAHA.120.15143

3. Wang X, Zhang H, Du H, Ma R, Nan Y, Zhang T. Risk factors for COVID-19 in patients with hypertension. Can J Infect Dis Med Microbiol. 2021;2021:5515941. doi:10.1155/2021/5515941

4. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671-1681.

5. CDC. Hypertension Prevalence in the U.S.: Million hearts®. Centers for Disease Control and Prevention. 2021. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html

6. Shah SJ, Stafford RS. Current trends of hypertension treatment in the United States. Am J Hypertens. 2017;30(10):1008-1014.

7. Yehualashet AS, Belachew TF. ACEIs and ARBs and their correlation with COVID-19: a review. Infect Drug Resist. 2020;13:3217-3224.

8. Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270. doi:10.1001/jamanetworkopen.2020.12270

9. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur J Int Med. 2020;76:97-99.

10. Peterson E, Lo KB, DeJoy R. The relationship between coronary artery disease and clinical outcomes in COVID-19: a single-center retrospective analysis. Coron Artery Dis. 2021;32(5):367-371.

11. Centers for Disease Control and Prevention. Facts about Hypertension. September 27, 2021. Accessed March 29, 2022. https://www.cdc.gov/bloodpressure/facts.htm

12. Huang Z, Cao J, Yao Y, et al. The effect of Ras blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med. 2020;8(7):430.

13. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N Engl J Med. 2020;382(25):2431-2440.

14. Reynolds HR, Adhikari S, Pulgarin C. Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N Engl J Med. 2020;382(25):2441-2448.

15. Gnanenthiran S, Borghi C, Burger D, et al. Renin Angiotensin system inhibitors in patients with Covid-19. American Heart Association Scientific Sessions. November 14, 2021. Accessed April 15, 2022. https://www.abstractsonline.com/pp8/?_ga=2.141042993.2042594723.1635046736-1021258137.1633710264#!/9349/presentation/18191

16. Li M, Wang Y, Ndiwane N. The association of covid-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. PLoS One. 2021;16(3):e0248652.

17. Székács B, Várbiró S, Debreczeni L. High-dose ACEi might be harmful in COVID-19 patients with serious respiratory distress syndrome by leading to excessive bradykinin receptor activation. Physiol Int. 2021;108:1-9 doi:10.1556/2060.2021.200007.10.1556/2060.2021.200007

18. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55(11):1466-1473. doi:10.1093/cid/cis733

19. Johnson EK, Nelson CP. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190(1):17-18. doi:10.1016/j.juro.2013.04.048

20. Suleiman AA, Suleiman A, Abdullahi UA, Suleiman SA. Estimation of the case fatality rate of COVID-19 epidemiological data in Nigeria using statistical regression analysis. Biosaf Health. 2021;3(1):4-7.

21. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3(8):e2017708.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Kumar S, Nikravesh M, Chukwuemeka U, et al. Safety of ACEI and ARB in COVID-19 management: A retrospective analysis. Clin Cardiol. 2022;45:759-766. doi:10.1002/clc.23836